European Oncology and Haematology最新文献_第5页

Oncological Scenario in Developing Countries – Little Light at the End of Tunnel 发展中国家的肿瘤情况——隧道尽头的微弱曙光

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.01

L. C. V. Suhag, Lt Col Sunita Bs, Lt Col Manu Chopra

引用次数: 0

Expert opinion on the treatment of refractory chronic phase chronic myeloid leukaemia 难治性慢性期慢性髓性白血病的治疗专家意见

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.17

T. Hughes, G. Saglio

引用次数: 1

Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting 洛拉匹坦在化疗引起的恶心和呕吐中的应用

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.120

B. Rapoport, P. Gascón, F. Scotté, K. Jordan, M. Maio, S. Börjeson, S. Ahmedzai

引用次数: 0

Molecular diagnostics in breast cancer routine practice 分子诊断在乳腺癌常规实践中的应用

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.74

N. T. Hoeve, C. Moelans, Willemijne A. M. E. Schrijver, W. D. Leng, P. Diest

引用次数: 1

Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer 激素受体阳性晚期乳腺癌患者的内分泌治疗策略

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.127

P. Schmid

引用次数: 1

Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis 嵌合抗原受体T细胞的临床开发和制造及白细胞分离的作用

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.28

A. Fesnak, U. O’Doherty

{"title":"Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis","authors":"A. Fesnak, U. O’Doherty","doi":"10.17925/EOH.2017.13.01.28","DOIUrl":"https://doi.org/10.17925/EOH.2017.13.01.28","url":null,"abstract":"A doptive transfer of chimeric antigen receptor (CAR) T cells is a powerful targeted immunotherapeutic technique. CAR T cells are manufactured by harvesting mononuclear cells, typically via leukapheresis from a patient’s blood, then activating, modifying the T cells to express a transgene encoding a tumour-specific CAR, and infusing the CAR T cells into the patient. Gene transfer is achieved through the use of retroviral or lentiviral vectors, although non-viral delivery systems are being investigated. This article discusses the challenges associated with each stage of this process. Despite the need for a consistent end product, there is inherent variability in cellular material obtained from critically ill patients who have been exposed to cytotoxic therapy. It is important to carefully select target antigens to maximise effect and minimise toxicity. Various types of CAR T cell toxicity have been documented: this includes “on target, on tumour”, “on target, off tumour” and “off target” toxicity. A growing body of clinical evidence supports the efficacy and safety of CAR T cell therapy; CAR T cells targeting CD19 in B cell leukemias are the best-studied therapy to date. However, providing personalised therapy on a large scale remains challenging; a future aim is to produce a universal “off the shelf” CAR T cell.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"56 1","pages":"28"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91034294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Advancing the Management of Non-small Cell Lung Cancer 推进非小细胞肺癌的治疗

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.53

David F Fakih

引用次数: 0

Adenocarcinoma in situ of the cervix - is loop electrosurgical excision procedure an acceptable alternative to cold knife cone biopsy? 宫颈原位腺癌-环电手术切除是一种可接受的替代冷刀锥活检方法吗?

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.24

M. Salcedo, A. Costales, M. Munsell, P. Ramalingam, R. Reis, A. Milbourne, P. Beitune, K. Schmeler

引用次数: 0

Plasmacytic Post-transplant Lymphoproliferative Disorder – Case Report 移植后浆细胞性淋巴细胞增生性疾病1例报告

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.01.80

J. Hanousek, J. Radocha, O. Souček, L. Plíšková, K. Kamarádová, A. Zavřelová, P. Žák

引用次数: 1

Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy 使T细胞募集到肿瘤作为改进过继T细胞治疗的策略

European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/eoh.2017.13.01.66

B. Cadilha, K. Dorman, F. Rataj, S. Endres, S. Kobold

{"title":"Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy","authors":"B. Cadilha, K. Dorman, F. Rataj, S. Endres, S. Kobold","doi":"10.17925/eoh.2017.13.01.66","DOIUrl":"https://doi.org/10.17925/eoh.2017.13.01.66","url":null,"abstract":"I mmunotherapy has successfully been implemented as the standard of care in a number of oncologic indications. A hallmark of cancer immunotherapy is the successful activation of T cells against cancer cells, leading to unparalleled efficacy for some tumour entities. However, current approved approaches are not specific, limiting both their activity and their safety. A more tailored way of using the therapeutic potential of T cells is adoptive T cell therapy, which encompasses ex vivo T cell manipulation and reinfusion to patients suffering from cancer. In haematologic malignancies such as acute lymphatic leukaemia of the B cell lineage, T cells modified with a chimeric antigen receptor against the B cell lineage antigen CD19 induce remissions in a high proportion of patients. In contrast, patients suffering from advanced solid tumours have shown little benefit from cell-based approaches. This is partly due to limited access of T cells to the tumour tissue, consequently restricting T cell activity. In this review, we focus on the limitations of T cell trafficking towards solid tumours. We summarise the existing knowledge on lymphocyte migration to understand how this pathway may be used to open therapeutic approaches for a broader range of indications. We also review new strategies targeting the tumour site that aid naturally occurring or gene-engineered T cells to migrate to solid tumours. Finally, we discuss how guiding T cells towards the tumour might contribute in harnessing their full cytolytic potential.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"28 1","pages":"66"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84527232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11